Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1206 in postmenopausal osteoporosis at high fracture risk
CTR20190726Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2019
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of QL1206 in osteoporosis, sponsored by Qilu Pharmaceutical. Started Jun 2019; status: completed.
02
Drugs
QL1206
03
Conditions
osteoporosis
Beyond the preview
Go deeper on CTR20190726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190726.